Grifols SA
Business
Grifols SA is a vertically integrated global producer of plasma-derived biological medicines and in vitro diagnostics, developing, manufacturing and distributing therapies based on plasma proteins. It offers plasma derivatives (including immunoglobulins, alpha-1 proteinase inhibitor, albumin, coagulation factors and fibrin sealants), hyperimmune products, diagnostic instruments, reagents and related hospital and infusion solutions. The company organizes operations into Plasma Procurement, Biopharma, Diagnostic, Bio Supplies and Others business units. Grifols markets products through subsidiaries and distributors across more than 100 countries, with direct presence in over 30 countries and multi-channel distribution to hospitals, blood banks, clinics, GPOs and governments.
Summary from filing dated 2025-04-11
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $500.00M |
| Total assets | $19.71B |
| Total liabilities | $12.11B |
| Stockholders' equity | — |
| Operating cash flow | — |